Cullen/Frost Bankers’s Allogene Therapeutics ALLO Stock Holding History

Cullen/Frost Bankers’s Portfolio ALLO Stock Details ALLO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$177	Sell	85 -59	-41%	-$130	﹤0.01%	1370
2026 Q1	$351	Sell	144 -414	-74%	-$830	﹤0.01%	1338
2025 Q4	$765	Sell	558 -4,395	-89%	-$5.8K	﹤0.01%	1324
2025 Q3	$6.14K	Buy	4,953 +2	+0%	+$2	﹤0.01%	1142
2025 Q2	$5.59K	Buy	4,951 +2,986	+152%	+$3.97K	﹤0.01%	1088
2025 Q1	$2.87K	Buy	1,965 +237	+14%	+$447	﹤0.01%	1119
2024 Q4	$3.68K	Buy	1,728 +177	+11%	+$437	﹤0.01%	1055
2024 Q3	$4.34K	Buy	1,551 +236	+18%	+$629	﹤0.01%	1023
2024 Q2	$3.06K	Buy	+1,315	New	+$3.88K	﹤0.01%	1032

Other funds holding ALLO

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Pfizer New York $170M AUM 191.09% 1-Year Est. Return

Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

TPG GP A Fort Worth, Texas $5B AUM 58.56% 1-Year Est. Return

SCM

Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Cullen/Frost Bankers's ALLO Position: Q2 2026 in Review

Cullen/Frost Bankers reduced its Allogene Therapeutics (ALLO) stake by 41% in Q2 2026, selling an estimated $130 and leaving 85 shares worth $177. The position accounts for ﹤0.01% of the portfolio, ranked #1370.

Cullen/Frost Bankers first reported a position in ALLO in Q2 2024 and has held it in 9 quarters since. The position peaked at $6.14K in Q3 2025. 209 funds tracked by Wall St. Rank hold ALLO as of Q2 2026.

Cullen/Frost Bankers held 85 shares of Allogene Therapeutics worth $177 as of Q2 2026.
Cullen/Frost Bankers sold 59 Allogene Therapeutics shares in Q2 2026, an estimated $130.
Allogene Therapeutics made up ﹤0.01% of Cullen/Frost Bankers's portfolio in Q2 2026, its #1370 holding.
Cullen/Frost Bankers first reported a position in Allogene Therapeutics in Q2 2024 and has held it in 9 quarters since.
Cullen/Frost Bankers's Allogene Therapeutics position peaked at $6.14K in Q3 2025.
209 funds tracked by Wall St. Rank held Allogene Therapeutics as of Q2 2026.

Based on Cullen/Frost Bankers's 13F filing for Q2 2026, filed 27 Jul 2026.